Clinical Trial Update: Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284) [Phase 2]

View source ↗

Summary

Phase 2 trial updating safety and efficacy when switching HIV regimen from Tenofovir/Emtricitabine plus protease inhibitor/ritonavir to a raltegravir plus nevir…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infections

Drugs mentioned

• Lamivudine (lamivudine)
• NEVIRAPINE (nevirapine)
• Raltegravir (raltegravir)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: HIV Infections | Phase 2 | Status: TERMINATED | Results posted: 2019-04-08